January 26-28, 2027 | Boston, Massachusetts

www.molecular-glue-summit.com

REGISTER BY OCTOBER 30 TO SAVE UP TO $800

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

5th Annual

Molecular Glue Drug Development Summit

Accelerating Rational Target-Specific Molecular Glue Design

Unlocking Novel Biology & Rational Design to Develop Potent, Selective & Safer Molecular Glues Against Cancer & Beyond

Expert Speakers Include:



Paul Lang
US Head of In Vitro Biology & Integrated Drug Discovery
Sanofi



Meizhong Jin
Senior Director of Oncology Chemistry
AstraZeneca



Emanuela Cuomo
Executive Director Global Head of Discovery Pharmacology
EMD Serono



Riccardo Sabatini
Chief Data Scientist
Orionis Biosciences



Anita Bellail
Chief Executive Officer
HB Therapeutics



Mat Sowa
Vice President, Lead Discovery
C4 Therapeutics

"This summit is the one forum that convenes pharma, biotech, and academia to tackle the key challenges facing the field, from glueability and next-generation screening to translational and clinical success. I'm looking forward to exchanging ideas with this community and helping shape the next wave of induced-proximity medicines."

Ajinkya Patil, Principal Scientist, **Pfizer - 2027 Speaker**

+1 617 455 4188 info@hansonwade.com

www.molecular-glue-summit.com

hansonwade

The Industry's Dedicated Summit for Molecular Glue Innovation

5th Annual Molecular Glue Drug Development Summit
January 26-28, 2027 | Boston, MA

From **Revolution Medicines' FDA approval of RASONQUE™** to major partnerships such as the **$1.4 billion Novartis-Orionis deal**, molecular glues are rapidly advancing from promising discovery tools to clinical reality. At the same time, researchers are expanding beyond cereblon-based degradation to explore novel ligases, non-degrading mechanisms, induced proximity biology, and applications beyond oncology, unlocking new therapeutic opportunities across previously inaccessible targets.

That's why the **5th Molecular Glue Drug Development Summit** returns as the industry's premier meeting dedicated exclusively to advancing molecular glues from breakthrough discovery to clinical success. **Join 70+ molecular glue leaders** from pharma, biotech, and academia to explore the latest advances in:

- **Glue discovery** – Discover emerging screening, profiling, and rational discovery approaches that enable the identification of higher-quality molecular glue candidates, helping teams expand target space and accelerate progression toward development
- **Induced proximity biology** – Explore novel mechanisms of induced proximity that go beyond degradation to stabilize, activate, inhibit, or rewire proteins, unlocking new therapeutic opportunities across previously inaccessible biology
- **AI-enabled design** – Learn how AI-powered platforms are accelerating target identification, glue optimization, and mechanism prediction, reducing discovery bottlenecks and increasing confidence in candidate selection
- **Translational science** – Gain practical insights into biomarker strategies, preclinical models, and translational frameworks that strengthen

Network with **CMOs**, **VPs**, **Executive Directors**, **Founders, Heads of Chemistry**, and **Academic KOLs**, forge new partnerships, and gain actionable insights to accelerate your next breakthrough.

What Past Attendees Have to Say


"This meeting serves as a catalyst for innovation bridging basic discovery and translation. Exploring new rational design frameworks and sensitive detection methods will advance our ability to systematically uncover and exploit molecular glue mechanisms"

Mikolaj Slabicki, Principal Investigator, **Massachusetts General Hospital**

"This meeting offers an opportunity to hear about a wide variety of strategies being employed to identify molecular glues and to connect with individuals who are bringing a high level of innovative problem solving to these challenges"

Patrick Arsenault, Senior Director, Lead Discovery, **Triana Biomedicines**

Key Highlights



Accelerate Discovery with Next-Generation Technologies
Discover how organizations including **Orionis Biosciences**, **AstraZeneca**, **Pfizer**, and **C4 Therapeutics** are combining AI, advanced screening, proteomics, and computational modelling to accelerate molecular glue discovery, improve hit identification, understand cooperativity, and move the field closer to rational design



Go Beyond Degradation & Unlock New Biology
Discover how organizations including **Rapafusyn**, **Coltac Therapeutics**, **St. Jude Children's Research Hospital**, and more are pushing molecular glues beyond protein degradation to stabilize, activate, inhibit, and rewire biology in entirely new ways across exciting applications in immunology, gene regulation, neurodegeneration, and other emerging disease areas



Expand the Molecular Glue Toolbox
Hear how innovators from **HB Therapeutics**, **Novartis**, **Fathom Therapeutics**, **TernaryTx**, and more are uncovering new ligases, novel substrates, and alternative discovery strategies to dramatically broaden the range of glueable targets while exploring what comes next beyond traditional cereblon biology and unlocking entirely new therapeutic opportunities



Turn Translational Insights into Patient Impact
Gain insights from **Bristol Myers Squibb**, **Nested Therapeutics**, **Canaan Partners**, **Novartis**, and other leaders on what it takes to translate exciting biology into successful therapies through emerging clinical data, translational lessons, investment perspectives, and practical approaches to de-risk development as molecular glues move closer than ever to delivering meaningful patient impact

+1 617 455 4188 info@hansonwade.com
www.molecular-glue-summit.com
hansonwade

What's New for Glues in 2027?

5th Annual Molecular Glue Drug Development Summit
January 26-28, 2027 | Boston, MA

Key Sessions Not to Be Missed

1 Accelerating Rational Molecular Glue Discovery

Featuring AstraZeneca, Orionis Biosciences, Pfizer & C4 Therapeutics

Explore how leading organizations are leveraging AI, automation, advanced screening technologies, proteomics, and mathematical modelling to improve hit identification, understand cooperativity, and accelerate the shift toward rational molecular glue design.

2 Unlocking New Biology with Induced Proximity

Featuring St. Jude Children's Research Hospital

Discover how molecular glues and synthetic regulators are being used to rewire gene expression and access previously undruggable biology, expanding the therapeutic potential of induced proximity beyond traditional degradation approaches.

3 Translating Molecular Glues into Clinical Success

Featuring BMS & Nested Therapeutics

Gain practical insights into advancing non-degrading molecular glues from discovery into the clinic, including translational strategies, early clinical lessons, and approaches to de-risk development as the field moves closer to delivering patient impact.

New Companies Presenting Include:

AstraZeneca · Bristol Myers Squibb · C4 Therapeutics · Fathom · EMD Serono · Nested Therapeutics · Orionis Biosciences · sanofi · Technetium Therapeutics · Pfizer · Ternary Tx · SK life science labs

Expand Your Network in 2027

- **70+** Molecular Glue Leaders Under One Roof
- **50%** Director-Level & Above Attendees
- **24+** Innovative Speakers
- **7+** Hours of Networking

What Our Expert Speakers Are Looking Forward To:

"Summits such as this are critical to help the field advance even faster as they offer opportunities to learn from these experts who are immersed in the field. I'm looking forward to several days of exciting science and strategic discussions around molecular glues."

Scott Edmondson, Senior Vice President, Chemistry, Nimbus Therapeutics

"I look forward to this summit as a unique forum to exchange ideas across chemical biology, structural biology, drug discovery, and translation, and to explore how molecular glues can unlock new therapeutic mechanisms beyond degradation."

Evripidis Gavathiotis, Professor of Biochemistry and of Medicine, **Albert Einstein College of Medicine**

+1 617 455 4188 info@hansonwade.com
www.molecular-glue-summit.com
hansonwade

Your Expert Speakers

Pharma Leaders:



Meizhong Jin
Senior Director of Oncology Chemistry
AstraZeneca



Felix Gonzalez
Scientific Director
Bristol Myers Squibb



Ryan Richards
Associate Principal Scientist, DMPK Modeling and Simulation
AstraZeneca



Emanuela Cuomo
Executive Director, Global Head of Discovery Pharmacology
EMD Serono



Jonathan Solomon
Associate Director
Novartis AG



Ajinkya Patil
Principal Scientist
Pfizer



Masaya Yamaguchi
Principal Scientist
Pfizer



Paul Lang
US Head of In Vitro Biology & Integrated Drug Discovery
Sanofi

Biotech Innovators:



Mat Sowa
Vice President, Lead Discovery
C4 Therapeutics



Antonio Lepore
Senior Associate
Canaan Partners



Gali Prag
Co-Founder & Board Member
Coltac Therapeutics



Asghar Razavi
Director of Molecular Modeling & Design
Fathom Therapeutics



Anita Bellail
Chief Executive Officer
HB Therapeutics



Bret Williams
Senior Vice President, Research
Magnet Biomedicine



Philip Komarnitsky
Chief Medical Officer
Nested Therapeutics



Scott Edmondson
Senior Vice President, Chemistry
Nimbus Therapeutics



Riccardo Sabatini
Chief Data Scientist
Orionis Biosciences



Rick Ewing
Vice President & Head of Chemistry
Rapafusyn



Corey Strickland
Vice President
SK Life Sciences Labs



Cheng Hu
Co-Founder & Chief Executive Officer
Technetium Therapeutics



Jeanine Harrigan
Vice President, Head of Biology
TernaryTx

Your Expert Speakers

Academic KOLs:



Evripidis Gavathiotis
Professor of Biochemistry, Medicine & Oncology
Albert Einstein College of Medicine



Chunhai Hao
Professor, Bicentennial Chair
Indiana University School of Medicine
Co-founder
Degrome Therapeutics



Yuhong Du
Associate Director of Assay Development and HTS
Emory Chemical Biology Discovery Center



Xiulei Mo
Associate Professor of Pharmacology & Chemical Biology
Emory University School of Medicine



Aseem Ansari
Chair, Chemical Biology & Therapeutics
St. Jude Children's Research Hospital

> "I look forward to this summit as a unique forum to exchange ideas across chemical biology, structural biology, drug discovery, and translation, and to explore how molecular glues can unlock new therapeutic mechanisms beyond degradation"

Evripidis Gavathiotis, Professor of Biochemistry and of Medicine,
Albert Einstein College of Medicine - 2027 Speaker

Pre-Conference | Workshop Day
Tuesday, January 26, 2027

Check-In & Coffee + Light Breakfast — 8.30

Workshop A — 9.00 - 12.00

Molecular Glue (MG) Discovery: Current Challenges and Paths Forward

Molecular glues hold promise to tackle high value protein targets and to unlock novel therapeutics. Mechanistically, molecular glues can reprogram protein function by stabilizing native protein interactions or creating neomorphic complexes that drive inhibition, activation, or degradation. However, prospective molecular glue discovery remains challenging because of uncertainty around protein-pair "glue-ability," limited ability to identify weak and rare screening hits, coupled with complex three-body thermodynamics, nonlinear SAR, and in certain cases biological constraints.
This workshop will discuss the key challenges associated with molecular glue discovery and optimization, in addition to how mathematical models can be used to integrate biochemical and cellular data to assess MG binding kinetics, cooperativity, performance, and provide rational, testable guidance for MG design.

Join this workshop to:

- Understand key challenges around MG discovery and optimization
- Explore mathematical modelling-guided design principles
- Discuss practical paths toward more rational molecular glue discovery

Workshop Leaders



Meizhong Jin
Senior Director, Oncology Chemistry
AstraZeneca



Ryan Richards
Associate Principal Scientist, DMPK Modeling and Simulation
AstraZeneca

Lunch Break & Networking — 12.00

Workshop B — 1.00 - 4.00

Finding the Right Hits Faster: Designing Screening & Prioritization Cascades for Molecular Glue Discovery

For many organizations, identifying a molecular glue hit is only the first hurdle. Determining whether that hit is mechanistically meaningful, clinically relevant, and worth the significant investment required for optimization remains one of the field's greatest challenges. Researchers increasingly recognize that no single screening technology is sufficient, leading to growing adoption of DELs, functional screening, in-cell discovery platforms, proteomics, and biophysical characterization methods. This workshop will examine how to construct robust screening and profiling cascades that distinguish genuine opportunities from false positives, establish confidence in mechanism of action, and support more informed go/no-go decisions throughout molecular glue discovery.

Join this workshop to:

- Compare DEL, functional, cellular, proteomic, and next-generation screening approaches to identify productive induced-proximity events and expand discovery beyond traditional cereblon-based degradation
- Design multi-parameter profiling cascades that evaluate cooperativity, selectivity, mechanism of action, and biological relevance using biophysical tools, proteomics, and disease-relevant cellular models

Workshop Leaders



Paul Lang
US Head of In Vitro Biology & Integrated Drug Discovery
Sanofi



Yuhong Du
Associate Director of Assay Development and HTS
Emory Chemical Biology Discovery Center



Masaya Yamaguchi
Principal Scientist
Pfizer

End Pre-Conference Workshop Day — 4.00

Conference Day One
Wednesday, January 27, 2027

7.50 **Check-In & Light Breakfast**



Anita Bellail
Chief Executive Officer
HB Therapeutics

8.50 **Chair's Opening Remarks**

Finding Needles in the Haystack: Next-Generation Molecular Glue Screening



Riccardo Sabatini
Chief Data Scientist
Orionis Biosciences
NEW COMPANY

9.00 **Towards Full Expansion of Ligase Platforms**

- Integrating artificial intelligence, robotics, and high-throughput experimentation to systematically identify productive induced-proximity events, accelerating molecular glue discovery at unprecedented scale
- Leveraging a purpose-built AI infrastructure designed specifically for molecular glue biology to uncover novel target-ligase relationships, expanding the searchable discovery landscape beyond traditional approaches
- Applying large-scale experimental and computational workflows to rapidly generate, validate, and prioritize molecular glue candidates, enabling faster progression from discovery to therapeutic development

9.30 **Panel Discussion: Can AI and Computational Methods Crack the Molecular Glue Code? Turning Predictions into Validated Hits**

- How can AI-powered and computational approaches be used to identify gluable surfaces, target-ligase pairings, and novel molecular glue opportunities, while integrating target selection with the practical challenge of finding tractable gluable interfaces?
- How can the molecular glue field overcome limited datasets to improve model training, predictive accuracy, and biological relevance, enabling more reliable AI-driven discovery workflows?
- How can computational predictions be most effectively combined with experimental screening, structural biology, and validation strategies to accelerate hit identification and optimize molecular glue potency and selectivity?



Scott Edmondson
Senior Vice President, Chemistry
Nimbus Therapeutics



Riccardo Sabatini
Chief Data Scientist
Orionis Biosciences



Cheng Hu
Co-Founder & Chief Executive Officer
Technetium Therapeutics



Jeanine Harrigan
Vice President, Head of Biology
TernaryTxs



Corey Strickland
Vice President
SK Life Sciences Labs
NEW COMPANY

10.00 **Decoding Glueability: Finding Better Molecular Glue Targets Faster**

- Leveraging new platform systematically map target-ligase interactions and identify productive induced-proximity events, expanding access to previously undruggable proteins
- Integrating functional screening, proteomics, and mechanistic profiling to rapidly validate molecular glue hits, improving confidence in target engagement and downstream biological activity
- Applying a target-first discovery strategy to uncover novel degrader opportunities across challenging protein classes, enabling more efficient progression from target selection to therapeutic candidate

10.30 **Morning Break & Speed Networking**

Join our speed networking session tailored for Molecular Glue professionals, like yourself, to connect with fellow industry peers to facilitate rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections within the space.

Conference Day One
Wednesday, January 27, 2027



Mat Sowa
Vice President, Lead Discovery
C4 Therapeutics
NEW COMPANY

11.30 From Library to Lead: Uncovering Unexpected Cooperativity in Molecular Glue Discovery

- Applying DNA-encoded libraries (DELs) to interrogate vast chemical space for rare and productive glue interactions, unlocking novel starting points against challenging targets
- Uncovering unexpected mechanisms of cooperativity in ternary complex formation, leading to higher quality hits and a more efficient discovery process
- Implementing a comprehensive downstream validation workflow to rapidly confirm on-target mechanism and accelerate the progression of validated hits toward lead optimization



Ajinkya Patil
Principal Scientist
Pfizer
NEW COMPANY

12.00 Proximity-First: A Multi-Tiered Molecular Glue Discovery Cascade for Undruggable Targets

- Anchoring hit identification on a highly sensitive, gain-of-signal biochemical proximity assay to maximize early detection of ternary-complex formation, opening a productive front-line screen for undruggable targets defined by weak or transient basal target and ligase interactions
- Sequencing a tiered validation cascade, spanning biochemical proximity, binder competition, functional ubiquitination, and cellular degradation, in which each tier enforces a distinct mechanistic criterion that systematically eliminates proximity-only false positives before committing chemistry resources
- Translating this orthogonally cross-validated funnel into confident go/no-go decisions and a generalizable, plug-and-play discovery framework that is portable across diverse undruggable targets and E3 ligases

12.30 Lunch Break & Networking

Breaking the Cereblon Paradigm: Exploring the Next Wave of Molecular Glue Biology



Anita Bellail
Chief Executive Officer
HB Therapeutics

1.30 Harnessing Endogenous Ligases to Expand the Reach of Molecular Glue Degradation

- Developing molecular glue degraders that leverage endogenous ligases beyond cereblon, expanding the range of induced-proximity mechanisms available for targeted protein degradation
- Applying novel ligase biology to challenging targets including KRAS and SREBF, unlocking therapeutic opportunities against proteins that have traditionally proven difficult to drug
- Establishing a new framework for molecular glue discovery beyond cereblon-dependent approaches, broadening the degrader toolbox and enabling the next generation of targeted therapies

> "This summit is the one forum that brings together pharma, biotech, and academia to tackle the key challenges and opportunities in the molecular glue field. I'm looking forward to the 2027 meeting and to exchanging ideas with cross-disciplinary experts to help advance the next wave of induced-proximity therapeutics"
>
> **Jeanine Harrigan**, Vice President, Head of Biology, **TernaryTx - 2027 Speaker**

Conference Day One
Wednesday, January 27, 2027



Jonathan Solomon
Associate Director
Novartis

2.00 Beyond Cereblon: A Target-Directed Approach to Molecular Glue Discovery

- Overcoming the field's reliance on Cereblon-first discovery by developing a target-directed strategy that expands molecular glue opportunities across new biological pathways
- Matching targets to the most suitable ligases through a mutagenesis-based approach, enabling discovery efforts beyond established Cereblon biology
- Building a more systematic framework for molecular glue discovery to uncover novel target-ligase pairings, broaden the druggable proteome, and accelerate first-in-class therapeutic opportunities

2.30 Afternoon Break & Poster Presentation Session

Take this opportunity to showcase your latest research and innovations with your peers and understand the strategies of your fellow Molecular Glue experts. Visit the website for the full T&Cs of submitting a poster

From Discovery to Patients: Delivering Clinical Success with Molecular Glues



Philip Komarnitsky
Chief Medical Officer
Nested Therapeutics
NEW COMPANY

3.30 From First-in-Human Studies to Clinical Validation: Advancing Non-Degrading Molecular Glues into Patients

- Advancing a novel non-degrading molecular glue from discovery through clinical development, demonstrating how induced-proximity therapeutics can generate therapeutic benefit beyond protein degradation
- Evaluating safety, pharmacokinetics, pharmacodynamic biomarkers, and early signals of activity from first-in-human studies to establish the clinical potential of non-degrading molecular glue therapies
- Sharing key translational and clinical learnings from programme progression to help de-risk future molecular glue development efforts and accelerate the path from innovative biology to patient impact

4.00 Panel Discussion: De-Risking Molecular Glue Development: What Does It Take to Build a Clinically and Commercially Successful Programme?

- How can developers integrate proteomics, mechanistic biology, translational biomarkers, and emerging clinical data to identify safety liabilities early and improve confidence in candidate selection?
- What are the most important scientific, clinical, regulatory, and commercial risks facing molecular glue programmes today, and how should biotech leaders, investors, and drug developers assess them when making development and funding decisions?
- As more molecular glues advance toward the clinic, what frameworks are needed to evaluate off-target effects, long-term biological consequences, and programme differentiation to enable informed go/no-go, partnering, and investment decisions?



Xiulei Mo
Associate Professor of Pharmacology and Chemical Biology
Emory University



Antonio Lepore
Senior Associate
Canaan Partners



Jonathan Solomon
Associate Director
Novartis



Philip Komarnitsky
Chief Medical Officer
Nested Therapeutics



Felix Gonzalez
Scientific Director
Bristol Myers Squibb
NEW COMPANY

4.30 Target Protein Degradation: Harnessing CRBN to Discover Potential Breakthrough Therapeutics

- Elucidating thalidomide's MoA led to realizing the promise of harnessing CRBN for targeted protein degradation
- Structural insight into cereblon ternary complexes is guiding the optimization of targeted protein degraders
- This platform is enabling the selective degradation of pathways implicated in multiple diseases



Anita Bellail
Chief Executive Officer
HB Therapeutics

5.00 Chair's Closing Remarks

5.15 End of Conference Day One

Conference Day Two
Thursday, January 28, 2027

8.00 **Check-In & Light Breakfast**



Rick Ewing
Vice President & Head of Chemistry
Rapafusyn

8.50 **Chair's Opening Remarks**

Engineering New Biological States with Non-Degrading Molecular Glues & Synthetic Regulators



Aseem Ansari
Chair of the Department of Chemical Biology & Therapeutics
St Jude Children Research Hospital

9.00 **Rewiring Gene Expression with Synthetic Gene Regulators to Access Previously Undruggable Biology**

- Harnessing synthetic gene regulators to induce targeted DNA-protein interactions and reprogram gene expression, expanding induced-proximity therapeutics beyond protein degradation
- Developing modular transcription-targeting platforms to selectively control disease-driving gene networks, unlocking therapeutic opportunities against previously intractable targets
- Translating synthetic gene regulation from foundational discovery to clinical development through scalable design principles and emerging therapeutic programmes, broadening the future scope of induced-proximity medicine



Evripidis Gavathiotis
Professor of Biochemistry & of Medicine
Albert Einstein College of Medicine
NEW INSTITUTION

9.30 **Allostery Meets Induced Proximity: Creating New Pharmacological States with Non-Degrading Molecular Glues**

- Leveraging molecular glues and allosteric modulators to selectively reprogram kinase signalling networks, enhancing target inhibition and unlocking synergistic therapeutic effects across oncogenic pathways
- Harnessing molecular glues to stabilize productive protein-protein interactions and activate selective cellular quality control mechanisms, expanding the biological outcomes achievable through induced proximity
- Exploring how induced protein interactions can reshape allosteric pharmacology and create new functional protein states, revealing therapeutic opportunities beyond conventional inhibition and degradation



Rick Ewing
Vice President & Head of Chemistry
Rapafusyn

10.00 **Targeting Transcription Factors with Non-Degrading Molecular Glues to Expand Therapeutic Opportunities Beyond Oncology**

- Harnessing non-degrading molecular glues to modulate transcription factor activity through induced proximity mechanisms, creating new opportunities to access historically challenging targets
- Demonstrating how STAT6-directed molecular glues can selectively reprogram immune signalling pathways, expanding the therapeutic potential of induced-proximity medicine beyond oncology applications
- Establishing a framework for the discovery and development of non-degrading molecular glues against immunological and transcriptional targets, broadening the future scope of the molecular glue modality

10.30 **Morning Break & Networking**

Conference Day Two
Thursday, January 28, 2027



Xiulei Mo
Associate Professor of Pharmacology and Chemical Biology
Emory University
NEW INSTITUTION

11.30 The Convergence of Genetic and Chemical Glues: Programming Protein Interaction Networks for Precision Therapeutics

- Introducing the concept of genetic glues—disease-associated mutations that rewire protein interaction networks—to establish a unified framework linking genetic perturbations with chemical glue pharmacology
- Demonstrating how mutation-directed and neo-cysteine molecular glues selectively reprogram disease-specific protein interaction networks, enabling therapeutic activation of previously undruggable tumor suppressors
- Presenting a next-generation discovery strategy that integrates cancer genetics, protein interaction network biology, and induced-proximity chemistry to expand molecular glue therapeutics beyond targeted protein degradation



Gali Prag
Co-Founder & Board Member
Coltac Therapeutics

12.00 Expanding Molecular Glue Discovery Beyond Degradation: Identifying Transcription Factor Inhibitors Through Conformational Trapping

- Overcoming the challenge of drugging transcription factors by developing a functional E. coli screening platform to identify molecular glues that trap proteins in inactive conformations
- Moving beyond degradation by selectively preventing transcription factor DNA binding and suppressing downstream gene expression through induced conformational control
- Combining computational screening and functional validation to rapidly discover potent molecular glue candidates and accelerate translation into cellular and in vivo models

12.30 Lunch Break & Networking

Beyond Oncology: Molecular Glues Across New Therapeutic Frontiers to Unlock Opportunities in High-Unmet-Need Diseases



Bret Williams
Senior Vice President, Research
Magnet Biomedicine

1.30 Harnessing Non-Degrading Molecular Glues to Rewire Immune Signalling & Expand Therapeutic Opportunities

- Leveraging non-degrading molecular glues to induce productive protein-protein interactions, expanding the induced proximity toolkit beyond targeted protein degradation
- Reprogramming immune signalling pathways through proximity-driven modulation of transcription factors and other immunological regulators, unlocking new therapeutic opportunities in immune-mediated diseases
- Advancing orally available small-molecule therapies that deliver biologics-like effects through targeted protein interaction control, broadening the clinical potential of molecular glues



Emanuela Cuomo
Executive Director, Global Head of Discovery Pharmacology
EMD Serono
NEW COMPANY

2.00 Rational Discovery of Molecular Glues and Proximity-Based Therapeutics Across Diverse Disease Areas

- Demonstrating how rational discovery approaches are enabling the identification of molecular glues and proximity-based therapeutics for targets and indications beyond oncology
- Exploring modality-agnostic strategies spanning molecular glues, PROTACs, and antibody-conjugated degraders to unlock new opportunities across autoimmune and neurological diseases
- Sharing lessons from advancing non-oncology degradation programs to accelerate the translation of induced proximity therapeutics into diverse disease areas

Conference Day Two
Thursday, January 28, 2027

2.30 Panel Discussion: Deploying Molecular Glues to Tackle Neurodegeneration's Toughest Targets

- How can molecular glues be leveraged to target pathogenic protein aggregates and drive the selective clearance of disease-causing proteins across Alzheimer's, Parkinson's, and Huntington's disease?
- What strategies are proving most effective for engineering brain-penetrant molecular glues that improve CNS exposure and target engagement while enhancing the translational potential of neurodegeneration programs?
- How can target engagement be most effectively validated in disease-relevant neuronal models to better understand therapeutic impact and de-risk progression into clinical development?



Rick Ewing
Vice President & Head of Chemistry
Rapafusyn



Charlie Hao
Chief Scientific Officer
Degron Therapeutics



Evripidis Gavathiotis
Professor of Biochemistry and of Medicine
Albert Einstein College of Medicine

3.00 Afternoon Break & Networking

Decoding Ternary Complex Formation: Predicting Productive Ternary Complexes at Scale



Jeanine Harrigan
Vice President, Head of Biology
TernaryTx
NEW COMPANY

3.30 Engineering Prospective, Rational Design of Molecular Glues

- Introducing our AI models Leopard, Puffin, Gecko and Octopus
- Applying the Ternary Platform to 'undruggable' targets
- GRIPs: small molecule RIPTACs



Asghar Razavi
Director of Molecular Modeling & Design
Fathom Therapeutics
NEW COMPANY

4.00 Proximal and Productive: A Transferable Free-Energy Based Conformational-Ensemble Engine for Ternary-Complex and Molecular Glue Discovery

- Mapping the free-energy based conformational ensemble for protein-protein interface rather than a single crystallographic pose enables ligandability of a pocket as a measurable quantity with a known free energy.
- Filtering the free-energy landscape for a productive ubiquitin transfer, i.e. lysine reach, residence time and turnover, identifies pockets with biological functional outcomes, not just a protein-protein glue.
- Ensemble-scale pharmacophore-based and generative AI based targeted virtual screening enables the discovery of functional molecular glues



Rick Ewing
Vice President & Head of Chemistry
Rapafusyn

4.30 Chair's Closing Remarks

4.45 End of 5th Molecular Glue Drug Discovery Summit

Partner With Us

5th Annual Molecular Glue Drug Development Summit
January, 26-28, 2027 | Boston, MA

The Industry's Flagship Meeting to Foster New & Existing Relationships within the Rapidly Expanding Molecular Glue Field

With **fresh clinical milestones**, major **partnerships**, and breakthrough **discovery technologies**, molecular glues are rapidly advancing toward clinical reality. The **5th Molecular Glue Drug Development Summit** brings together senior leaders from **pharma**, **biotech**, and **academia** to explore the latest advances, spark new collaborations, and build the partnerships shaping the future of the field.


Showcase Your Innovation
Put your technology, platform, or service in front of the molecular glue community as it searches for new ways to discover glues, unlock novel biology, and accelerate candidates into the clinic. Demonstrate how your expertise can help solve the field's toughest challenges.

Meet the Right People
Connect directly with decision-makers and senior scientists across pharma, biotech, and academia. With **70+** molecular glue leaders, including **CMOs**, **VPs** & **Executive Directors**, every conversation can spark a new partnership, collaboration, or customer relationship.

Create New Partnerships
As companies pursue novel ligases, non-degrading glues, and increasingly complex targets, the need for trusted partners continues to grow. Build relationships with the organizations advancing the next generation of molecular glue therapies.


Stay Close to the Science
Gain a front-row seat to breakthroughs in **rational design**, **novel ligases**, **AI-enabled discovery**, **proteomics**, and **translational development**. Understand emerging industry priorities and position your solutions where they can deliver the greatest impact.

Seniority of Attendees



- Executive Leadership 23%
- Directors & Heads of 27%
- Scientists & Academics 50%

Type of Companies Attending



*Statistics Taken from 4th Molecular Glue Drug Development Summit

Get Involved



Samuel Turner
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.molecular-glue-summit.com/register/

Tel: +1 617 455 4188

Email: info@hansonwade.com

DISCOVER the breakthrough technologies, novel biological mechanisms, and emerging therapeutic opportunities reshaping molecular glue drug discovery across oncology and beyond

BUILD actionable expertise in rational glue discovery, induced proximity biology, translational science, and clinical development to accelerate your programs with greater confidence

ENGAGE directly with the scientists and decision-makers driving the field forward to create collaborations, uncover new opportunities, and stay ahead of the next wave of molecular glue innovation

Drug Developers	Register by Date, October 30th 2026 & Save Up to $800	On the Door Price
Conference + Pre-Conference Workshop Day	$3,707	$4,507
Conference Only	$2,749	$3,149

Academic & Research Institutes**	Register by Date, October 30th 2026 & Save Up to $800	On the Door Price
Conference + Pre-Conference Workshop Day	$3,107	$3,907
Conference Only	$2,349	$2,749

Solution & Service Providers	Register by Date, October 30th 2026 & Save Up to $400	On the Door Price
Conference + Pre-Conference Workshop Day	$4,997	$5,397
Conference Only	$3,599	$3,999

*To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Hyatt Regency Boston Harbor
101 Harborside Dr, Boston, MA 02128, United States
https://www.hyatt.com/hyatt-regency/en-US/bosha-hyatt-regency-boston-harbor

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom